SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Walsh G Biopharmaceutical Benchmarks Nature Biotechnology, 28: 917924 (2010).
  • 2
    Reichert JM. Metrics for antibody therapeutics development. MAbs; 2: 695700 (2010).
  • 3
    Hou JJC, Codamo J, Pilbrough W, Hughes B, Gray PP Munro TP, New frontiers in cell line development: challenges for biosimilars. Journal of Chemical Technology and Biotechnology, 86: 895904 (2011).
  • 4
    Dietmair S, Nielsen LK Timmins NE, Engineering a mammalian super producer. Journal of Chemical Technology and Biotechnology, 86: 905914 (2011).
  • 5
    Falconer RJ, Jackson-Matthews D Mahler SM, Analytical strategies for assessing comparability of biosimilars. Journal of Chemical Technology and Biotechnology, 86: 915922 (2011).
  • 6
    Codamo J, Hou JJC, Hughes BS, Gray PP Munro TP, Efficient mAb production in CHO cells incorporating PEI-mediated transfection, mild hypothermia and the co-expression of XBP-1. Journal of Chemical Technology and Biotechnology, 86: 923934 (2011).
  • 7
    Song M, Raphaelli K, Jones ML, Aliabadi-Zadeh K, Leung KM Crowley D, et al, Clonal selection of high producing, stably transfected HEK293 cell lines utilizing modified, high-throughput FACS screening. Journal of Chemical Technology and Biotechnology, 86: 935941 (2011).
  • 8
    Falconer RJ, Chan C, Hughes K, Trent P Munro TP, Stabilization of a monoclonal antibody during purification and formulation by addition of basic amino acid excipients. Journal of Chemical Technology and Biotechnology, 86: 942948 (2011).